Panel
Getting Our Health Priorities in Order: Prevention, Research, and Treatment
Milken InstituteEd Greissing, Katie Couric, Mark Alles, Tom Beauregard, Linda Fried, Eric Lefkofsky, Jim Robinson
- Core Premise: A critical misalignment exists between the determinants of health and current spending priorities; 70% of health outcomes are driven by prevention (behavior, environment, social factors), yet the U.S. allocates only 5% of healthcare dollars to public health initiatives.
- Obesity as a Primary Driver: Obesity-related healthcare costs are estimated at $300 billion annually, a figure equivalent to the total annual spending on all pharmaceutical treatments for all diseases combined.
- UnitedHealth's Diabetes Strategy: UnitedHealth Group has shifted from traditional group models to virtual prevention programs, specifically "Project Not Me" (a reality show) and "Real Appeal," to increase engagement in diabetes prevention without stigmatizing "pre-diabetes."
- The "Real Appeal" model is a free, virtual weight loss program that has achieved a 5% weight loss reduction, lowering the risk of progression to Type 2 diabetes by 50%, matching the efficacy of clinical trials with higher scalability.
- Celgene's Focus on "Interception": The biopharmaceutical sector is prioritizing early-stage intervention ("interception") to treat diseases before they manifest, leveraging biomarkers rather than tissue types to identify at-risk populations.
- Early detection via screening (e.g., breast and colorectal cancer) is identified as a binary determinant of survival, curing patients if caught early versus leading to metastatic death.
- Tempus and Data Scarcity: A major bottleneck in oncology progress is the lack of comprehensive data; the Cancer Genome Atlas contains fewer than 20,000 genomes, which is insufficient to identify patterns for rare mutations (e.g., only four patients exist for specific dual mutations in pancreatic cancer).
- Technology as an Enabler: The cost of genomic sequencing has dropped one million-fold over 12 years (from $1 million to $1), creating an unprecedented opportunity to integrate clinical, molecular, and phenotypic data for precision medicine.
- Regulatory Friction: Current regulatory frameworks and antiquated approval processes for drugs and devices are cited as significant barriers to adopting new technologies and real-world evidence, necessitating a shift from homogeneity-based testing to adaptive, data-driven frameworks.
- Frailty as a Medical Syndrome: Gerontological research defines frailty not as a single organ failure but as the "unraveling" of multi-system physiologic regulation, which is modifiable through early prevention strategies like sustained physical activity.
- Prevention ROI: Preventive investments yield massive returns; for example, a "group prenatal care" model piloted by UnitedHealth reduced preterm births by 30% and repeat pregnancies by 50%, demonstrating the value of social support in clinical outcomes.
- Innovation in Immunotherapy: Immunotherapy is described as a "Star Wars" breakthrough, with checkpoint inhibitors enabling remission in previously terminal cases (e.g., James Carter's melanoma), though challenges remain in treating solid tumors which are often "invisible" to the immune system.
- Drug Pricing and Value: Pharmaceutical R&D costs are cited at $1–2 billion per drug, with pivotal registration studies costing approximately $100 million; however, the cost of delivery and administration (90 cents of every dollar) far exceeds the cost of the medicine itself (10 cents).
- Access Disparities: A stark life expectancy gap exists, with privileged populations enjoying 9+ years longer life expectancy compared to those lacking access to prevention and health promotion.
- Socioeconomic determinants now drive a divergence in health outcomes, with U.S. health status slipping to the bottom of peer nations over the last 20 years due to these disparities.
- Future Outlook: The panel collectively agrees that the convergence of technology, data science, and clinical practice represents the first historical moment where physicians acknowledge they cannot perform their jobs without digital infrastructure to process molecular and clinical data.
- Consensus on Next Steps: The immediate priority is the creation of uniform, interoperable data platforms to enable real-time decision-making, moving from siloed, episodic data collection to integrated, longitudinal patient profiles.